A prognostic score for patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization.

ABSTRACT:

Background

Intermediate-stage hepatocellular carcinoma (HCC), defined according to the Barcelona Clinic Liver Cancer (BCLC) staging system, is a heterogeneous condition with variable clinical benefits from transarterial chemoembolization (TACE). This study aimed to develop a simple validated prognostic score based on the predictive factors for survival in patients with intermediate-stage HCC treated with TACE.

Methods

Three-hundred and fifty patients with intermediate-stage HCC undergoing initial TACE at Chiba University Hospital (training cohort; n = 187) and two affiliated hospitals (validation cohort; n = 163) were included. Following variables were entered into univariate and multivariate Cox regression models to develop a points-based clinical scoring system: gender, ag

SUBMITTER: Ogasawara S 

PROVIDER: S-EPMC4412579 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature